In the ED, T 102.6, BP 115/60, HR 113 (AF w/ RVR).
EKG showed AF with increased ST depressions with TWI 1I, avL, II, V2-V6.
Given INR 4.2 and HCT 29, he received a total of 5 u FFP and 5 u PRBC.
PVD 8.
Left total hip replacement in [**2115**] with a repeat replacement in [**2123**] 12.
Previous angiography with left iliac stenting in [**8-/2132**] 14.
Physical Exam: Vitals: T 98.3  P 80 BP 109/51 MAP 71 18 O2 sats 98% on RA GEN: patient lying in bed talking on phone, NAD HEENT: AT, EOMI, MMM no lesions, neck supple, no JVD CV: irregular rate, no murmurs, rubs, gallops Pulm: crackles at bases b/l Ext: R foot: mid tarsal amputation- clean, well-healed; L foot large oozing ulcer on lateral aspect of foot immediately inferior to fifth metetarsal, fifth metatarsal blackened and deformed; multiple smaller black ulcers at base of toes Neuro: A & O x3, CN II-XII grossly intact; 5/5 strength in LE BL, toe tap intact   Pertinent Results: [**2133-5-24**] 12:25PM BLOOD WBC-12.0*# RBC-3.29* Hgb-9.2* Hct-29.5* MCV-90 MCH-28.0 MCHC-31.2 RDW-14.3 Plt Ct-152 [**2133-5-26**] 04:14AM BLOOD WBC-9.8 RBC-3.59* Hgb-10.4* Hct-31.3* MCV-87 MCH-29.1 MCHC-33.4 RDW-14.9 Plt Ct-87* [**2133-6-1**] 09:15AM BLOOD WBC-7.4 RBC-3.43* Hgb-9.9* Hct-31.4* MCV-91 MCH-28.7 MCHC-31.5 RDW-16.0* Plt Ct-128* [**2133-6-7**] 05:40AM BLOOD WBC-5.4 RBC-3.55* Hgb-10.1* Hct-33.3* MCV-94 MCH-28.4 MCHC-30.3* RDW-15.1 Plt Ct-150 [**2133-5-24**] 12:25PM BLOOD Neuts-81.6* Bands-0 Lymphs-10.1* Monos-8.2 Eos-0.1 Baso-0 [**2133-6-1**] 09:15AM BLOOD Neuts-50 Bands-0 Lymphs-36 Monos-9 Eos-2 Baso-0 Atyps-3* Metas-0 Myelos-0 NRBC-1* [**2133-5-24**] 12:25PM BLOOD Hypochr-2+ Anisocy-1+ Poiklo-NORMAL Macrocy-NORMAL Microcy-NORMAL Polychr-NORMAL [**2133-5-24**] 12:25PM BLOOD PT-25.3* PTT-36.5* INR(PT)-4.2 [**2133-6-8**] 09:06AM BLOOD PT-19.3* PTT-81.5* INR(PT)-2.5 [**2133-5-29**] 12:30PM BLOOD ESR-15 [**2133-5-24**] 12:25PM BLOOD UreaN-57* Creat-1.7* Na-139 K-6.4* Cl-106 HCO3-17* AnGap-22* [**2133-6-8**] 02:07AM BLOOD Glucose-83 UreaN-20 Creat-1.4* Na-141 K-4.1 Cl-105 HCO3-26 AnGap-14 [**2133-5-24**] 12:25PM BLOOD ALT-23 AST-29 CK(CPK)-83 AlkPhos-179* Amylase-31 TotBili-0.6 [**2133-5-25**] 01:18PM BLOOD CK(CPK)-1183* DirBili-0.2 [**2133-5-27**] 06:40AM BLOOD ALT-328* AST-432* CK(CPK)-418* AlkPhos-165* TotBili-0.8 [**2133-6-7**] 05:40AM BLOOD ALT-27 AST-29 LD(LDH)-371* AlkPhos-155* Amylase-28 TotBili-0.6 [**2133-5-24**] 12:25PM BLOOD Calcium-8.7 Phos-3.0 Mg-1.7 Iron-25* [**2133-6-8**] 02:07AM BLOOD Phos-3.4 Mg-1.9 [**2133-5-24**] 12:25PM BLOOD calTIBC-259* VitB12-573 Folate-16.1 Hapto-178 Ferritn-96 TRF-199* [**2133-6-1**] 09:15AM BLOOD Triglyc-60 HDL-42 CHOL/HD-2.2 LDLcalc-39 [**2133-5-24**] 12:25PM BLOOD TSH-6.4* [**2133-5-24**] 10:30PM BLOOD Free T4-0.9* [**2133-5-24**] 12:25PM BLOOD Cortsol-41.3* [**2133-5-24**] 12:25PM BLOOD CRP-76.9* [**2133-5-29**] 12:30PM BLOOD CRP-54.1* [**2133-5-25**] 05:38AM BLOOD Lactate-2.2*  [**2133-5-25**] 5:09 pm SWAB      Source: Left foot.
WOUND CULTURE (Final [**2133-5-28**]):       ENTEROBACTER CLOACAE.
SENSITIVITIES: MIC expressed in MCG/ML  _________________________________________________________                              ENTEROBACTER CLOACAE                              |          SERRATIA MARCESCENS                              |          | CEFEPIME--------------     2 S      <=1 S CEFTAZIDIME-----------  =>64 R      <=1 S CEFTRIAXONE-----------  =>64 R      <=1 S CIPROFLOXACIN---------   =>4 R GENTAMICIN------------   <=1 S        2 S IMIPENEM--------------   <=1 S        2 S LEVOFLOXACIN----------   =>8 R   <=0.25 S MEROPENEM-------------<=0.25 S   <=0.25 S PIPERACILLIN---------- =>128 R      <=4 S PIPERACILLIN/TAZO-----              <=4 S TOBRAMYCIN------------   <=1 S        4 S     ANAEROBIC CULTURE (Final [**2133-5-29**]):    NO ANAEROBES ISOLATED.
[**2133-5-27**] Echocardiogram: EF 30 %, The left atrium is markedly dilated.
Overall left ventricular systolic function is moderately depressed with global hypokinesis.
Left ventriculography was not preformed given the renal dysfunction and recent echocardiogram showing EF of 30%.
Limited hemodynamics showed slightly elevated left ventricular filling pressures with LVEDP of 21 mm Hg.
1) Hematemesis: Upper endoscopy revealed [**Doctor First Name **]-[**Doctor Last Name **] tear which was treated with epinephrine and cautery.
He received 5 units PRBCs and 5 units FFP and his hematocrit stabilized.
His hematocrit was monitored and Coumadin and ASA were held until several days post-bleed.
Foot x-ray revealed osteomyelitis and swab of lesions showed Enterobacter clocae resistant to b-lactam and fluoroquinolones and he was started on imipenem on [**2133-5-28**].
He required no more transfusions and his hematocrit was stable.
On the day of discharge his hematocrit 33.6.
His cardiac enzymes were elevated but trended down.
His cardiac catheterization this admission showed severe 3 vessel disease requiring CABG.
Will follow with his PCP to check his LFTs now that he is on a Statin.
7)Atrial fibrillation with RVR in the setting of acute upper GI bleed: After initial presentation rate has been well controlled with metoprolol XL 250 mg po q day.
He was restarted on Coumadin after his procedures and current INR is 2.5 (goal [**12-25**]).
He will be discharged on Coumadin 3 mg po q daily and his INR will be followed at the rehabilitation facility.
Creatinine has been stable at 1.3-1.4 for several before discharge.
His creatinine will be monitored on an outpatient basis.
HCTZ 25 mg po qd 5. coumadin 2.5 mg po q Mon, Tues, Thurs, Fri, Sat 6. coumadin 5 mg po qsun, wed  Discharge Medications: 1.
Osteomyelitis of 5th metarsal Secondary 1.
PVD 5.
Rheumatoid arthritis   Discharge Condition: Hemetemesis resolved, Hct stable, afebrile on imipenam, INR therapeutic on coumadin  Discharge Instructions: Please monitor for chest pain and monitor creatinine for worsening renal failure.
Also watch for temperature > 101.
Provider: [**First Name11 (Name Pattern1) **] [**Last Name (NamePattern1) 4340**], MD Where: LM [**Hospital Unit Name 4341**] DISEASE Phone:[**Telephone/Fax (1) 457**] Date/Time:[**2133-6-30**] 10:30  Please call ([**Telephone/Fax (1) 1504**] to schedule follow-up with cardiothoracic surgery for your bypass in [**12-26**] weeks.
